Additionally, clinicians should consider the potential benefits of using targeted treatments for AD, such as baricitinib (JAK1/2 inhibitor) and dupilumab (anti-IL-4Rα), which have been shown to have potential benefits in treating moderate to severe AA (66–68). This evidence concerns the gene JAK1 and Alzheimer disease.